Tenax Therapeutics (TENX) Asset Writedowns and Impairment (2011 - 2016)

Tenax Therapeutics (TENX) has 4 years of Asset Writedowns and Impairment data on file, last reported at $33.3 million in Q4 2016.

• For the quarter ending Q4 2016, Asset Writedowns and Impairment changed N/A year-over-year to $33.3 million; the trailing twelve-month figure through Dec 2016 stood at $33.3 million (changed N/A YoY), and the FY2016 full-year result was $33.3 million, up 3114.44% from the prior year.
• Asset Writedowns and Impairment climbed to $33.3 million in Q4 2016, from $24110.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $33.3 million in Q4 2016 to a low of $24110.0 in Q2 2013.
• A 3-year average of $8.4 million and a median of $60423.5 in 2012 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment tumbled 90.81% in 2012 and slipped 13.14% in 2013, its largest moves.
• Tracing TENX's Asset Writedowns and Impairment over 3 years: stood at $27758.0 in 2012, then decreased by 13.14% to $24110.0 in 2013, then surged by 137872.21% to $33.3 million in 2016.
• Business Quant data shows TENX's Asset Writedowns and Impairment at $33.3 million in Q4 2016, $24110.0 in Q2 2013, and $27758.0 in Q2 2012.